CartiHeal announced two-year results of a pivotal Investigational Device Exemption study (IDE). The study was conducted to test the potential superiority of the Agili-C™ implant vs. microfracture and debridement for the treatment of joint surface lesions, chondral and osteochondral defects, in the knee joint. The IDE study is a multicenter, 2:1 randomized, open-labeled and controlled trial. 251 Subjects, 167 in the Agili-C™ arm and 84 in the SSOC arm, were enrolled in 26 sites in the U.S. and outside the U.S.
The primary endpoint for this study was the change from baseline to 24 months in average of the 5 subscales of the Knee injury and Osteoarthritis Outcome Score (KOOS Overall): Pain, Other Symptoms, Quality of Life – QOL, Activities of Daily Living – ADL and Sports. The KOOS Overall Score ranges from 0 to 100, where higher values represent better outcomes.
The data generated from this trial demonstrated superiority of Agili-C to the current surgical standard of care (debridement or microfracture). The Bayesian posterior probability of superiority at Month 24 was determined to be 1.000, exceeding the prespecified threshold of 0.98 required to demonstrate superiority.
“Study results, which demonstrate the superiority of the Agili-C implant over the current surgical standard of care, offers an important potential benefit, as reflected in our Breakthrough Designation by the FDA, for patients who lack other sufficient treatment options,” said Nir Altschuler, CartiHeal’s founder and CEO. “We are looking forward to working closely with the FDA and plan to submit the PMA application later this year.”
CartiHeal announced two-year results of a pivotal Investigational Device Exemption study (IDE). The study was conducted to test the potential superiority of the Agili-C™ implant vs. microfracture and debridement for the treatment of joint surface lesions, chondral and osteochondral defects, in the knee joint. The IDE study is a multicenter, 2:1...
CartiHeal announced two-year results of a pivotal Investigational Device Exemption study (IDE). The study was conducted to test the potential superiority of the Agili-C™ implant vs. microfracture and debridement for the treatment of joint surface lesions, chondral and osteochondral defects, in the knee joint. The IDE study is a multicenter, 2:1 randomized, open-labeled and controlled trial. 251 Subjects, 167 in the Agili-C™ arm and 84 in the SSOC arm, were enrolled in 26 sites in the U.S. and outside the U.S.
The primary endpoint for this study was the change from baseline to 24 months in average of the 5 subscales of the Knee injury and Osteoarthritis Outcome Score (KOOS Overall): Pain, Other Symptoms, Quality of Life – QOL, Activities of Daily Living – ADL and Sports. The KOOS Overall Score ranges from 0 to 100, where higher values represent better outcomes.
The data generated from this trial demonstrated superiority of Agili-C to the current surgical standard of care (debridement or microfracture). The Bayesian posterior probability of superiority at Month 24 was determined to be 1.000, exceeding the prespecified threshold of 0.98 required to demonstrate superiority.
“Study results, which demonstrate the superiority of the Agili-C implant over the current surgical standard of care, offers an important potential benefit, as reflected in our Breakthrough Designation by the FDA, for patients who lack other sufficient treatment options,” said Nir Altschuler, CartiHeal’s founder and CEO. “We are looking forward to working closely with the FDA and plan to submit the PMA application later this year.”
Copy to clipboard 
